Diversified Trust Co Cuts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Diversified Trust Co cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 24.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,606 shares of the medical research company's stock after selling 3,178 shares during the quarter. Diversified Trust Co's holdings in Thermo Fisher Scientific were worth $4,780,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $25,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. Noble Wealth Management PBC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $35,000. Finally, Cassady Schiller Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 89.2% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after buying an additional 33 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.3%

Shares of NYSE:TMO opened at $412.02 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The stock's 50-day moving average price is $410.11 and its two-hundred day moving average price is $484.47. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The firm has a market cap of $155.53 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 2.17 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.11 earnings per share. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TMO shares. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. UBS Group lowered their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Evercore ISI cut their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada dropped their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $604.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.